Barclays Cuts Agilent Technologies (NYSE:A) Price Target to $140.00

Key Points

• Barclays cut Agilent's price target to $140 (from $150) while keeping an "overweight" rating, with the new target implying roughly a 16.28% upside from the prior close.
• Analysts are mixed but generally positive: the consensus rating is "Moderate Buy" with a consensus price target of $160.53, even as several firms (Wells Fargo, Morgan Stanley, UBS) trimmed targets and Evercore upgraded to "outperform."
• Shares traded at $120.40 after Agilent slightly missed quarterly EPS, and the company set FY2026 guidance of $5.900–$6.040; the stock has a ~$34.0B market cap and a 12‑month range of $99.12–$160.27.

Agilent Technologies (NYSE:A - Get Free Report) had its price objective reduced by equities research analysts at Barclays from $150.00 to $140.00 in a report issued on Tuesday,Benzinga reports. The firm currently has an "overweight" rating on the medical research company's stock. Barclays's target price would indicate a potential upside of 16.28% from the stock's previous close.

A has been the subject of several other research reports. Wells Fargo & Company decreased their target price on Agilent Technologies from $175.00 to $165.00 and set an "overweight" rating for the company in a research note on Thursday, February 26th. Morgan Stanley decreased their target price on Agilent Technologies from $180.00 to $160.00 and set an "overweight" rating for the company in a research note on Tuesday, March 3rd. Evercore raised Agilent Technologies from an "in-line" rating to an "outperform" rating and raised their target price for the stock from $155.00 to $160.00 in a research note on Monday, January 5th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Agilent Technologies in a research note on Monday, December 29th. Finally, UBS Group decreased their target price on Agilent Technologies from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Thursday, February 26th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $160.53.

Agilent Technologies Price Performance

Shares of A stock traded up $2.90 on Tuesday, hitting $120.40. 2,676,901 shares of the company's stock were exchanged, compared to its average volume of 2,192,072. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.07 and a quick ratio of 1.59. Agilent Technologies has a 12 month low of $99.12 and a 12 month high of $160.27. The stock has a market cap of $34.03 billion, a P/E ratio of 26.58, a price-to-earnings-growth ratio of 2.42 and a beta of 1.30. The company has a 50 day moving average of $118.99 and a 200 day moving average of $134.13.

Agilent Technologies (NYSE:A - Get Free Report) last posted its earnings results on Wednesday, February 25th. The medical research company reported $1.36 EPS for the quarter, missing the consensus estimate of $1.37 by ($0.01). The firm had revenue of $1.80 billion during the quarter, compared to the consensus estimate of $1.81 billion. Agilent Technologies had a net margin of 18.26% and a return on equity of 24.49%. Agilent Technologies's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.31 earnings per share. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. On average, equities research analysts predict that Agilent Technologies will post 5.58 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Brighton Jones LLC raised its stake in shares of Agilent Technologies by 6.1% in the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company's stock valued at $626,000 after buying an additional 270 shares during the period. Jones Financial Companies Lllp raised its stake in shares of Agilent Technologies by 15.9% in the first quarter. Jones Financial Companies Lllp now owns 5,610 shares of the medical research company's stock valued at $602,000 after buying an additional 769 shares during the period. Geneos Wealth Management Inc. raised its stake in shares of Agilent Technologies by 54.8% in the first quarter. Geneos Wealth Management Inc. now owns 599 shares of the medical research company's stock valued at $70,000 after buying an additional 212 shares during the period. Acadian Asset Management LLC raised its stake in shares of Agilent Technologies by 16.5% in the first quarter. Acadian Asset Management LLC now owns 5,352 shares of the medical research company's stock valued at $625,000 after buying an additional 758 shares during the period. Finally, Sivia Capital Partners LLC bought a new stake in shares of Agilent Technologies in the second quarter valued at $273,000. Hedge funds and other institutional investors own 87.41% of the company's stock.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.